Zhi Tong Cai Jing·2025-08-11 11:05Core Viewpoint - Fosun Pharma has signed a licensing agreement with Expedition for the global development, production, and commercialization of the investigational product XH-S004, excluding mainland China and Hong Kong and Macau [1] Group 1: Licensing Agreement Details - The agreement allows Expedition to develop and commercialize XH-S004 globally, while Fosun Pharma retains rights for development and commercialization in mainland China and Hong Kong and Macau [1] - Expedition will pay up to $120 million in non-refundable upfront payments and milestone payments related to development and regulatory achievements [1] - Additionally, Expedition may pay up to $525 million in sales milestone payments based on annual net sales performance of the licensed product in the licensed regions [1] Group 2: Product Information - XH-S004 is a small molecule oral DPP-1 inhibitor developed by Fosun Pharma, aimed at reducing inflammation and blocking the cycle of infection and airway structural damage [1] - Potential indications for XH-S004 include non-cystic fibrosis bronchiectasis and chronic obstructive pulmonary disease [1] Group 3: Strategic Implications - This collaboration is expected to accelerate the clinical development and commercialization of the licensed product globally [1] - The partnership will also help expand Fosun Pharma's innovative product portfolio in international markets [1]